Skip to main content

Table 7 Bacterial spectrum and resistance (R) against nitroxoline (Ni) versus controls (C), cotrimoxazole or norfloxacin, at study entry (visit 1)

From: Review of the literature and individual patients’ data meta-analysis on efficacy and tolerance of nitroxoline in the treatment of uncomplicated urinary tract infections

Study Nr./R NWNF 10 R(n) NWNF 11 R(n) NWNF 13 R(n) NWNF 15 R(n) NWNF 10–13 R(n) NWNF 10–15 R(n)
Bacterial isolates n (%) Ni/C n (%) Ni/C n (%) Ni/C n (%) Ni/C n (%) Ni/C n (%) Ni/C
E. coli 82(67.2%) -/1 88(65.3%) 1/6 81(67.0%) −/− 98(73.0%) −/− 251(66.4%) 1/7 349(68.2%) 1/7
Proteus spp.* 20(16.4%) −/− 9(6.7%) −/− 8(6.6%) −/− 12(9.0%) −/− 37(9.8%) −/− 49(9.6%) −/−
Klebsiella spp. 1(0.8%) −/− 5(3.7%) −/− 1(0.8%) −/− 6(4.5%) −/− 7(1.9%) −/− 13(2.5%) −/−
Enterobacter spp. - - 2(1.5%) −/− 3(2.5%) −/− 7(5.2%) -/2 5(1.3%) −/− 12(2.3%) -/2
Citrobacter spp. 2(1.6%) −/− - −/− 1(0.8%) −/− 1(0.8%) −/− 3(0.8%) −/− 4(0.8%) −/−
Enterococci 9(7.4%) −/− 13(9.7%) 6/1 13(10.7%) -/1 2(1.5%) −/− 35(9.3%) 6/2 37(7.2%) 6/2
Staphylococci 5(4.1%) −/− 7(5.2%) −/− 13(10.7%) 1/- 8(6.0%) −/− 25(6.6%) 1/- 33(6.4%) 1/-
Streptococci 2(1.6%) −/− 2(1.5%) −/− 1(0.8%) −/− - −/− 5(1.3%) −/− 5(1.0 %) −/−
Others 1(0.8%) −/− 9(6.7%) −/− - −/− - −/− 10(2.6%) −/− 10(2.0%) −/−
Total 122(100%) -/1 135(100%) 7/7 121(100%) 1/1 134(100%) -/2 378(100%) 8/9 512(100%) 8/11
-/0.8%   5.2/5.2%   0.8/0.8%   -/1.5%   2.1/2.4% 1.6/2.1%
Isolates/patients 122/122   135/115   121/105   134/116   378/350   512/466  
(1.0) (1.17) (1.15) (1.16) (1.08) (1.1)
  1. *indol positive and negative strains.